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Ba
zCOBJECTIVES The purpose of this study was to compare the 1-year outcome between bioresorbable vascular scaffold
(BVS) and everolimus-eluting metallic stent (EES) in ST-segment elevation myocardial infarction (STEMI) patients.
BACKGROUND The Absorb BVS (Abbott Vascular, Santa Clara, California) is a polymeric scaffold approved for treat-
ment of stable coronary lesions. Limited and not randomized data are available on its use in ST-segment elevation
myocardial infarction (STEMI) patients.
METHODS This study included 290 consecutive STEMI patients treated by BVS, compared with either 290 STEMI
patients treated with EES or 290 STEMI patients treated with bare-metal stents (BMS) from the EXAMINATION (A Clinical
Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-segment Elevation Myocardial
Infarction) trial, by applying propensity score matching. The primary endpoint was a device-oriented endpoint (DOCE),
including cardiac death, target vessel myocardial infarction, and target lesion revascularization, at 1-year follow-up.
Device thrombosis, according to the Academic Research Consortium criteria, was also evaluated.
RESULTS The cumulative incidence of DOCE did not differ between the BVS and EES or BMS groups either at 30 days
(3.1% vs. 2.4%, hazard ratio [HR]: 1.31 [95% conﬁdence interval (CI): 0.48 to 3.52], p ¼ 0.593; vs. 2.8%, HR: 1.15 [95%
CI: 0.44 to 2.30], p ¼ 0.776, respectively) or at 1 year (4.1% vs. 4.1%, HR: 0.99 [95% CI: 0.23 to 4.32], p ¼ 0.994; vs.
5.9%, HR: 0.50 [95% CI: 0.13 to 1.88], p ¼ 0.306, respectively). Deﬁnite/probable BVS thrombosis rate was numerically
higher either at 30 days (2.1% vs. 0.3%, p ¼ 0.059; vs. 1.0%, p ¼ 0.324, respectively) or at 1 year (2.4% vs. 1.4%,
p ¼ 0.948; vs. 1.7%, p ¼ 0.825, respectively), as compared with EES or BMS.
CONCLUSIONS At 1-year follow-up, STEMI patients treated with BVS showed similar rates of DOCE compared
with STEMI patients treated with EES or BMS, although rate of scaffolds thrombosis, mostly clustered in the early phase,
was not negligible. Larger studies with longer follow-up are needed to conﬁrm our ﬁndings. (J Am Coll Cardiol Intv
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190T he ABSORB trials have shown thesafety and feasibility of everolimus-eluting bioresorbable vascular scaf-
fold (BVS) (Abbott Vascular, Santa Clara,
California) implantation in patients with
stable angina or silent ischemia and with
de novo nonthrombotic coronary artery
lesions, with many physiological advantages
of BVS over metallic prosthesis and a low
rate of major adverse cardiovascular events
up to 4-year follow-up (1,2).SEE PAGE 198The physiological advantages of BVS, such
as late lumen enlargement and vasomotion,
appear particularly appealing for the treat-
ment of ST-segment elevation myocardial
infarction (STEMI) (3). Recent studies have
shown short-term safety and feasibility of
BVS implantation in STEMI patients (4,5).However, those data are limited by lack of a control
group, small sample size, and short-term follow-up.
In addition, some reports of scaffold thrombosis have
recently raised concerns about actual BVS safety in a
thrombotic milieu, such as STEMI, especially in light
of the very low incidence of such events with second-
generation drug-eluting metallic stents, reported in
recent trials and meta-analyses (5–10).
We therefore conducted an analysis by matching
consecutive STEMI patients receiving BVS at 6 cen-
ters with the cohorts of STEMI patients receiving
everolimus-eluting stents (EES) (Xience V, Abbott
Vascular) and bare-metal stent (BMS) (Multilink
Vision, Abbott Vascular) from the EXAMINATION (A
Clinical Evaluation of Everolimus Eluting Coronary
Stents in the Treatment of Patients With ST-segment
Elevation Myocardial Infarction) trial, with the aim to
compare the 1-year device-oriented endpoint (DOCE)
between the 2 groups.
METHODS
STUDY POPULATION. All consecutive STEMI patients
treated by BVS between December 2012 and June 2013lty of Medicine, Charles University in Prague, University Hosp
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analysis. All baseline clinical and procedural charac-
teristics were retrospectively collected. We used
propensity score to match each STEMI patient treated
by BVS to a comparable STEMI patient treated by
everolimus-eluting Xience V stent or by BMS (see
the Statistical Methods section for further details).
Patients from the controlled EXAMINATION trial,
randomized to Xience V or BMS, were used for
matching with BVS patients (7).
Percutaneous coronary intervention (PCI) was
performed according to conventional clinical prac-
tice: manual thrombus aspiration, glycoprotein (GP)
IIb/IIIa inhibitors, heparin, and bivalirudin adminis-
tration were performed according to operator’s
choice. Balloon pre-dilation was not mandatory but
was recommended for BVS implantation, according to
BVS instructions for use. Dual antiplatelet therapy
with aspirin plus clopidogrel, ticagrelor, or prasugrel
was prescribed in all patients for 12 months. Of note,
neither prasugrel nor ticagrelor were approved during
the recruitment period of the EXAMINATION trial.
The investigators of each institution who partici-
pated in the study were asked to complete a struc-
tured patient-level database including a series of key
baseline clinical and procedural data as well as the
clinical outcome data, similar to the EXAMINATION
database. Such individual patient data were sent to
the study coordinator (S.B.), who was responsible for
checking data consistency and for ﬁnal pooling in a
single database.
The 1-year follow-up was performed in the
EXAMINATION patients by clinical visits and in the
BVS patients either by clinical visit or telephone calls.
Clinical follow-up in BVS patients was pre-speciﬁed
in all institutions because of the involvement of
these patients in local BVS registries.
This is an observational and retrospective study,
performed according to the privacy policy of the
various institutions that participate and to their reg-
ulations for the appropriate use of data in patient-
oriented research, which are based on international
regulations, including the Declaration of Helsinki.ital Kralovske Vinohrady, Prague, Czech Republic;
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191Moreover, as the BVS has the CE (Conformité
Européenne) mark for clinical use without any re-
striction in terms of clinical presentation, it can be
routinely used in different settings including STEMI
without a speciﬁc written informed consent in addi-
tion to the standard informed consent to the proce-
dure. Patients from the EXAMINATION trial had
signed informed consent to participate in that trial.
Because the present analysis is based on propensity
matching and no randomization was performed, no
additional consent is required.
DEFINITION OF CLINICAL OUTCOMES. The primary
endpoint of this analysis was deﬁned as the com-
bined DOCE, including cardiac death, target vessel
myocardial reinfarction, and target lesion revascu-
larization. All individual components and device
thrombosis (stent/scaffold), deﬁned by the Academic
Research Consortium criteria, were also analyzed (11).
Whereas all events in the EXAMINATION trial were
adjudicated by an independent clinical events com-
mittee that was blinded to stent assignment after
review of original source documentation, all events in
the BVS group were adjudicated by investigators
collecting any relevant medical records, discharge
letters, and documentation of hospital stay from
the hospitals providing treatment and physicians in
private practice, using the same deﬁnitions of events
applied in the EXAMINATION trial. (7,12)
STATISTICAL ANALYSIS. For the present analyses,
individual data were pooled on a patient-level basis.
Continuous variables are expressed as mean  SD,
and categorical variables are presented as absolute
number and proportion (%). Overall comparisons
between nonmatched groups were performed by the
t test for continuous variables and by chi-square or
Fisher exact test when the Cochran rule was not met
for categorical variables.
Propensity score matching was applied to compare
the 1-year device-oriented primary endpoint of STEMI
patients treated with BVS and those treated with EES
or BMS. A propensity score matching was performed
using a proprietary macro developed and tested for
SPSS version 20.0 (SPSS Inc., Chicago, Illinois). First,
the program performed a logistic regression to score
all patients according to the treatment (BVS vs. EES;
BVS vs. BMS), using as covariates clinical and proce-
dural parameters that were clinically relevant for the
endpoint: age (years), sex (male/female), diabetes
mellitus (yes/no), and culprit vessel and stent/scaf-
fold length and diameter (mm). Second, the macro
searched and selected the best match case of the EES
group and BMS group for every BVS case according to
the absolute value of the difference between thepropensity score of EES/BMS and BVS cases under
consideration. Patients in the 2 groups were matched
through a greedy algorithm based on local optimiza-
tion (13). The control selected for a particular case was
the one closest to the case in terms of distance,
whereby the maximum allowed distance for matching
was set to 0.10. Analyses were then performed on the
2 matched groups (EES vs. BVS and BMS vs. BVS),
stratiﬁed by pairs to account for propensity score
matching.
Time-to-event variables are presented as Kaplan-
Meier curves. Hazard ratios (HRs) of all events at
30 days and 1 year were calculated with Cox propor-
tional hazards models. The validity of the propor-
tionality assumption was veriﬁed for all covariates by
a visual examination of the log (minus log) curves and
a test based on Schoenfeld residuals. Because it was
not met for treatment, HRs by Cox regression were
estimated separately into the timeframes up to
30 days and from 1 to 12 months.
A Cox regression model was developed to adjust
the DOCE between the EES and BVS groups for use of
GP IIb/IIIa inhibitors (yes/no) and use of clopidogrel
versus other platelet inhibitors (ticagrelor/prasugrel).
Two other Cox regression models were also devel-
oped to compare deﬁnite/probable device thrombosis
between the EES and BVS groups, adjusting sepa-
rately for use of GP IIb/IIIa inhibitors (yes/no) and use
of clopidogrel versus others (ticagrelor or prasugrel),
to avoid any overﬁtting due to the small number of
events. A 2-sided p value <0.05 was considered
statistically signiﬁcant. All statistical analyses were
performed using SPSS version 20.0.
RESULTS
STUDY POPULATION. A total of 290 consecutive
STEMI patients, treated by BVS implantation, were
collected for this analysis among the various in-
stitutions. In the EXAMINATION trial, 751 and 747
STEMI patients were randomly assigned to receive
EES or BMS, respectively. Of those who received EES,
17 withdrew informed consent, and 14 were missed
during follow-up, leaving 734 patients who were used
as a control group for matching with BVS. Of those
who received BMS, 6 withdrew informed consent,
and 15 were missed during follow-up, leaving 726
patients who were used as control group for matching
with BVS. Online Table A shows baseline clinical and
procedural characteristics in the overall population.
By applying the aforementioned methodology
of the propensity score matching, all 290 BVS patients
were matched with either 290 EES patients or 290
BMS patients (Table 1).
TABLE 1 Baseline Clinical and Procedural Characteristics
BVS Group
(n ¼ 290)
EES Group
(n ¼ 290)
BMS Group
(n ¼ 290) p Value* p Value†
Age, yrs 56.01  12.75 57.57  12.01 56.62  11.83 0.090 0.363
Male 236 (81.4) 231 (79.7) 245 (84.5) 0.141 0.115
Smoking history 177 (61.0) 220 (75.9) 236 (81.4) 0.005 <0.001
Hypertension 144 (49.7) 127 (43.8) 135 (46.6) 0.835 0.560
Diabetes 37 (12.8) 37 (12.8) 33 (11.4) 0.886 0.876
Dyslipidemia 121 (41.7) 132 (45.5) 104 (36.0) 0.115 0.137
Previous MI 10 (3.5) 10 (3.5) 14 (4.8) 0.838 0.927
Previous PCI 10 (3.4) 11 (3.8) 7 (2.4) 0.287 0.350
Previous CABG 3 (1.0) 1 (0.3) 1 (0.3) 0.234 0.573
Previous stroke 6 (2.1) 5 (1.7) 5 (1.7) 0.828 0.622
Infarct-related artery 0.188 0.486
LAD 145 (50.0) 117 (40.3) 124 (42.8)
RCA 114 (39.3) 126 (43.4) 127 (43.8)
LCx 29 (10.0) 45 (15.5) 38 (13.1)
SVG 1 (0.3) 0 (0) 0 (0)
Left main 1 (0.3) 2 (0.7) 1 (0.3)
Multivessel disease 24 (8.2) 28 (9.7) 21 (7.2) 0.768 0.872
Thrombectomy
device use
217 (74.8) 199 (68.6) 197 (68.0) 0.513 0.144
Pre-dilation 230 (81.0) 83 (29.0) 87 (30.5) <0.001 <0.001
GP IIb/IIIa inhibitor 196 (67.6) 150 (51.7) 159 (54.8) 0.003 0.174
Bivalirudin 0 (0) 20 (6.9) 21 (7.2) 0.957 0.957
Unfractionated heparin 290 (100) 231 (79.7) 235 (81.0) 0.925 0.930
Number of stents/
scaffold
1.14  0.39 1.13  0.37 1.15  0.40 0.587 0.790
Stent/scaffold
diameter, mm
3.22  0.33 3.19  0.40 3.23  0.40 0.348 0.906
Stent/scaffold
length, mm
22.53  8.80 21.78  9.17 22.08  8.53 0.128 0.363
Post-dilation 105 (36.3) 44 (15.2) 33 (11.4) <0.001 <0.001
TIMI ﬂow grade pre <0.001 0.178
0 202 (69.7) 159 (55.2) 170 (58.8)
1 15 (5.2) 18 (6.2) 28 (9.7)
2 34 (11.7) 44 (15.3) 36 (12.5)
3 39 (13.4) 67 (23.3) 55 (19.0)
TIMI ﬂow grade post 0.244 0.478
0 1 (0.3) 5 (1.7) 2 (0.7)
1 1 (0.3) 1 (0.3) 2 (0.7)
2 13 (4.5) 7 (2.4) 10 (3.4)
3 275 (94.8) 275 (95.5) 276 (95.2)
Values are mean  SD or n (%). *Comparison between BVS and EES. †Comparison between BVS and BMS. The p
values are from paired t test for continuous data and conditional logistic regression for dichotomous and ordinal
data.
BMS ¼ bare-metal stent; BVS ¼ bioresorbable vascular scaffold; CABG ¼ coronary artery by-pass graft; EES ¼
everolimus-eluting stent; GP ¼ glycoprotein; LAD ¼ left anterior descending artery; LCx ¼ left circumﬂex artery;
MI ¼ myocardial infarction; PCI ¼ percutaneous coronary intervention; RCA ¼ right coronary artery; SVG ¼
saphenous vein graft; TIMI ¼ Thrombolysis In Myocardial Infarction.
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192After propensity score matching, patient de-
mographics were comparable between the matched
groups, except for history of smoking, which was
more prevalent in the BVS group.
With regard to procedural characteristics, the BVS
and EES groups differ in the device implantation
technique used, with higher use of pre- and post-
dilation in the BVS than in the EES group. Whereas
pre-PCI Thrombolysis In Myocardial Infarction (TIMI)ﬂow was lower in the BVS than in the EES group, no
differences were found in post-PCI TIMI ﬂow. A
higher rate of GP IIb/IIIa inhibitor use was found in
the BVS group than in the EES group. A higher rate of
pre- and post-dilation was also found in the BVS than
in the BMS group.
Whereas all EES and BMS patients were on aspirin
and clopidogrel, BVS patients were taking clopidogrel
(33.3%), ticagrelor (32.9%), or prasugrel (33.8%) in
addition to aspirin.
The 1-year follow-up data were available in 100%
of BMS and EES patients and in 98% of BVS patients,
due to 4 patients lost to follow-up.
CLINICAL OUTCOMES BETWEEN BVS AND EES.
At 1 year, no differences were found between the 2
groups with regard to the DOCE (HR: 0.94 [95% con-
ﬁdence interval (CI): 0.23 to 4.32], p ¼ 0.994), even
after adjustment for GP IIb/IIIa inhibitors and clopi-
dogrel (HR: 1.50 [95% CI: 0.24 to 9.50], p ¼ 0.662)
(Table 2). The DOCE was also not different between
the BVS and EES groups at 30 days (HR: 1.31 [95% CI:
0.48 to 3.52], p ¼ 0.593) (Figure 1A). No differences
were found in its individual components either at
30 days or 1 year (Table 2).
At 1 year, the deﬁnite/probable device thrombosis
rate was not different between the groups (HR: 1.10
[95% CI: 0.69 to 17.54], p ¼ 0.948), also after
adjustment for clopidogrel (HR: 2.94 [95% CI: 0.18 to
47.08], p ¼ 0.445) or GP IIb/IIIa inhibitor use (HR:
1.59 [95% CI: 0.10 to 25.43], p ¼ 0.743) (Figure 1B).
Within 30 days after implantation, early deﬁnite/
probable device thrombosis rate tended to be higher
in the BVS than in the EES group (2.1% vs. 0.3%, p ¼
0.059), whereas no differences were found in terms
of early deﬁnite device thrombosis (1.4% vs. 0.3%,
p ¼ 0.341).
One BVS thrombosis occurred in a patient with
2 BVS overlapped, who stopped the prescribed anti-
platelet therapy (aspirin þ ticagrelor) 3 days before
the event; no other patients with device thrombosis
withdrew any antiplatelet agent (Table 3).
CLINICAL OUTCOMES BETWEEN BVS AND BMS.
Either at 30 days or at 1 year, no differences were
found between the 2 groups (Table 2). Figures 1C and 1D
show Kaplan-Meier curves for the DOCE and deﬁnite/
probable device thrombosis.
DISCUSSION
This is the ﬁrst study comparing BVS versus EES
versus BMS in STEMI patients, based on propensity
score matching. The main ﬁndings of the present
study can be summarized as follows. 1) The 30-day
TABLE 2 Clinical Outcome at 30 Days and 1 Year
BVS Group
(n ¼ 290)
EES Group
(n ¼ 290)
BMS Group
(n ¼ 290) HR [95% CI]* p Value* HR [95% CI]† p Value†
Clinical outcome at 30 days
DOCE 9 (3.1) 7 (2.4) 8 (2.8) 1.31 (0.48–3.52) 0.593 1.15 (0.44–2.30) 0.776
Cardiac death 5 (1.7) 4 (1.4) 5 (1.7) 1.27 (0.34–4.72) 0.724 1.01 (0.30–3.50) 0.981
TV MI 4 (1.4) 2 (0.7) 0 (0) 4.00 (0.45–35.79) 0.215 6.64 (0.02–20.68) 0.306
TLR 3 (1.0) 2 (0.7) 3 (1.0) 1.50 (0.25–8.98) 0.657 1.02 (0.20–5.06) 0.979
Deﬁnite/probable device thrombosis 6 (2.1) 1 (0.3) 3 (1.0) 6.00 (0.72–49.84) 0.059 2.00 (0.50–8.32) 0.324
Deﬁnite device thrombosis 4 (1.4) 1 (0.3) 1 (0.3) 3.00 (0.31–28.84) 0.341 4.00 (0.45–35.86) 0.214
Clinical outcome at 1 year‡
DOCE 12 (4.1) 12 (4.1) 17 (5.9) 0.94 (0.23–4.32) 0.994 0.50 (0.13–1.88) 0.306
Cardiac death 6 (2.1) 6 (2.1) 6 (2.1) 0.87 (0.08–9.90) 0.908 2.46 (0.15–40.43) 0.528
TV MI 6 (2.1) 4 (1.4) 3 (1.0) 1.65 (0.28–9.90) 0.583 2.52 (0.62–10.31) 0.198
TLR 5 (1.7) 4 (1.4) 10 (3.4) 1.93 (0.25–14.91) 0.527 0.95 (0.15–5.85) 0.955
Deﬁnite/probable device thrombosis 7 (2.4) 4 (1.4) 5 (1.7) 1.10 (0.69–17.54) 0.948 0.79 (0.07–9.20) 0.852
Deﬁnite device thrombosis 5 (1.7) 2 (0.7) 2 (0.7) 1.10 (0.70–17.66) 0.944 1.19 (0.74–19.03) 0.902
*Comparison between BVS and EES. †Comparison between BVS and BMS. ‡HRs have been estimated in the timeframe after 30 days up to 1 year.
CI ¼ conﬁdence interval; DOCE ¼ device-oriented endpoint; HR ¼ hazard ratio; TLR ¼ target lesion revascularization; TV ¼ target vessel; other abbreviations as in Table 1.
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193and 1-year DOCE rates appear to be acceptable among
the groups. 2) Some concerns may be raised about
BVS thrombosis, especially in the early phase after
implantation, compared with the EES group; although
no deﬁnite conclusions could be drawn given the
small sample size, these ﬁndings should be inter-
preted with caution. 3) Despite propensity matching,
there were signiﬁcant differences between groups in
the implantation technique, with higher use of
balloon pre- and post-dilation associated with BVS
compared with other groups.
A lot of attention has been recently focused on BVS
use in STEMI, as thrombotic lesions, which are most
frequently thin-cap ﬁbroatheromas, rich in necrotic
core and covered by a thin ﬁbrous cap (<65 mm), may
represent the best scenario for the BVS “vascular
restoration therapy” (14). Autopsy studies suggested
that metallic struts embedded in necrotic core may
remain uncovered even in the long term and thus
potentially be a trigger for stent thrombosis (15).
Conversely, BVS, which in the long term are
completely replaced by connective tissue and smooth
muscle cells, may overcome the problem of metal
persistence into the coronary vessel wall and may at
the same time stabilize a thin-cap ﬁbroatheroma with
a neointimal layer (3). In addition, from a physiolog-
ical perspective, the absence of permanent vessel
caging facilitates the restoration of vasomotor func-
tion, adaptive shear stress, cyclic strain, and late
lumen enlargement (14).
The ﬁrst few data published on BVS in acute cor-
onary syndrome showed safety and feasibility of its
implantation; however, all these reports were limitedby lack of a randomized control group, very small
sample size, and short-term follow-up (4,16,17). In
addition, some concerns have been recently raised on
the high thrombogenicity of BVS in a thrombotic
milieu, such as STEMI (5,6,18). Given this back-
ground, our analysis collected individual data from 6
high-volume centers with large experience in BVS
implantation in STEMI, allowing us to have the
largest current cohort of STEMI treated by BVS.
By using a propensity score matching with STEMI
treated by EES or BMS, a comparison of these thera-
peutic strategies was performed. In this regard, the
EXAMINATION trial, which randomized 1,501
all-comer STEMI patients 1:1 to EES versus BMS,
provided perfect controlled EES and BMS groups to
build a propensity score (7).
We found that at 1 year, DOCE was not different
between BVS and EES or BMS. It is noteworthy that,
compared with the EXAMINATION trial, our selected
EES and BMS population had a DOCE rate slightly
lower (4.1% vs. 5.9% and 5.9% vs. 8.4%, respec-
tively), was younger, and had less incidence of dia-
betes. Of note, taking as reference the DOCE rate of
the EES group in the EXAMINATION trial, our anal-
ysis would have been 80% powered to demonstrate
superiority of BVS over EES (7). Despite a lower DOCE
rate, 1-year deﬁnite/probable EES thrombosis rate
was higher than that of the EXAMINATION trial (1.4%
vs. 0.9%); this ﬁnding translated to a lack of statis-
tically signiﬁcant difference compared with deﬁnite/
probable BVS thrombosis at 1 year, but with a trend
toward a higher early device thrombosis in the BVS
than in the EES group, without any effect on 30-day
FIGURE 1 Kaplan-Meier Curves for the Comparison Between BVS and Either EES or BMS
(A) Kaplan-Meier event curves comparing bioresorbable vascular scaffold (BVS) and everolimus-eluting stents (EES) for the composite device-oriented
endpoint (DOCE) of cardiac death, target vessel myocardial infarction, and target lesion revascularization. (B) Kaplan-Meier event curves comparing BVS and
EES for deﬁnite/probable device thrombosis. (C) Kaplan-Meier event curves comparing BVS and bare-metal stents (BMS) for the composite DOCE of cardiac
death, target vessel myocardial infarction, and target lesion revascularization. (D) Kaplan-Meier event curves comparing BVS and BMS for the deﬁnite/
probable device thrombosis. The dotted line on the vertical axis indicates the 30-day time point.
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194DOCE. In contrast, the 1-year deﬁnite/probable BMS
thrombosis rate was lower than that of the EXAMI-
NATION trial (1.7% vs. 2.5%), being therefore
numerically lower than BVS thrombosis despite theabsence of statistically signiﬁcant difference. A mat-
ter of chance or differences in periprocedural vari-
ables or in-device material (metal vs. polymer) and
in-strut thickness (BVS: 150 mm vs. EES: 90 mm) may
TABLE 3 Cases of Deﬁnite DT in the BVS and EES Groups
Case #
Type of
Device Device Size (mm) Location of MI
Timing of DT (Days After the
Primary Procedure)
Use of
GP IIb/IIIa
Antiplatelet Regimen
at the Time of DT
1 BVS 3.0  28 LAD 96 No ASA þ clopidogrel
2 BVS 3.5  18 RCA 1 Yes ASA þ ticagrelor
3 BVS Two 3.5  12 overlapped LAD 13 No ASA and ticagrelor stopped
3 days before the event
4 BVS 3.0  18 RCA 0 No ASA þ prasugrel
5 BVS 3.5  28 LCx 0 Yes ASA þ clopidogrel
6 EES 3.0  18 RCA 0 Yes ASA þ clopidogrel
7 EES 3.5  23 LCx 35 No ASA þ clopidogrel
ASA ¼ aspirin; DT ¼ device thrombosis; other abbreviations as in Tables 1 and 2.
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195be advocated to explain these ﬁndings, which in any
case should be considered as hypothesis-generating
and conﬁrmed in future trials powered for this
safety endpoint. In particular, a reduction in strut
thickness, which will take place in the new BVS
generation, will probably represent an important step
forward in this regard.
In comparison with a previous large-scale ran-
domized trial, 1-year BVS DOCE rate was found to be
comparable to other second-generation DES, based
on biodegradable polymer (8), and lower than ﬁrst-
generation DES, mainly driven by lower rate of
target lesion revascularization (19,20). Conversely,
1-year deﬁnite/probable BVS thrombosis (2.4%)
appeared to be higher than that reported in a recent
meta-analysis for second-generation DES in STEMI
(1.7% for EES and biolimus-eluting stents), almost
resembling that of ﬁrst-generation DES (3.2% for
paclitaxel-eluting stents and 3.4% for sirolimus-
eluting stents) (9,19,20). Importantly, compared
with EES, the increased risk of deﬁnite BVS throm-
bosis appears to be similar to the increased risk with
the zotarolimus-eluting Resolute stent (Medtronic,
Santa Rosa, California) (relative risk [RR]: 2.47 [95%
CI: 1.24 to 4.96]), biodegradable-polymer–based
thick-strut stent (RR: 2.04 [95% CI 1.27 to 3.35]), and
BMS (RR EES/BMS: 0.32 [95% CI: 0.11 to 0.78]) (10,21).
These concerns about BVS thrombosis are in line with
the recently published all-comer GHOST (Gauging
coronary Healing with biOresorbable Scaffolding
plaTforms) registry, which showed 2.1% incidence of
deﬁnite/probable BVS thrombosis at 6 months,
mostly clustered within 30 days after implantation
(22). A learning curve of the operators involved in BVS
implantation cannot be excluded, although previous
reports were not able to demonstrate a signiﬁcant
effect of the learning curve on clinical outcomes of
patients treated with the Absorb BVS (22). It is note-
worthy that although the Cox model adjusted for new
antiplatelet drugs did not show any difference indeﬁnite/probable device thrombosis between the
groups, any inﬂuence of these drugs on such
endpoint cannot be excluded, given the small number
of patients. It may be hypothesized that a higher use
of new antiplatelet agents in the EES arm, potentially
reducing incidence of device thrombosis, would make
the trend herein toward a higher device thrombosis
statistically signiﬁcant in the BVS versus EES arm. A
sensitivity analysis, comparing only those patients
taking clopidogrel in both groups (overall 194 pa-
tients), showed higher device thrombosis in the BVS
than in the EES group (3.1% vs. 1.0%, p ¼ 0.312),
which was not statistically signiﬁcant due to the small
sample size.
It is important to highlight that variables related
to lesion preparation were not used in propensity
score matching. This decision was based on the
rationale that, in daily clinical practice, balloon pre-
dilation is highly recommended in the case of BVS
implantation (23). For this reason, in a hypothetical
STEMI randomized trial comparing BVS with a
metallic DES lesion, preparation by means of
thrombectomy or balloon pre-dilation would not be
mandatory by protocol but left to the operator’s
decision, as, for example, in the ABSORB TROFI-II
trial (NCT01986803), which is currently random-
izing STEMI patients to BVS versus EES. It is also
important to note that GP IIb/IIIa inhibitor use, left
to operator discretion, could translate to higher us-
age in BVS than metallic DES, especially in light of
recent reports encouraging optimization of antith-
rombotic/antiplatelet regimen in the case of BVS
implantation (5). Nevertheless, after adjusting either
for GP IIb/IIIa inhibitor use or for usage of new an-
tiplatelet agents (ticagrelor/prasugrel), which could
have favored the BVS arm, our analysis did not show
any difference between groups in terms of DOCE.
It is interesting to note that the higher use of
balloon pre-dilation in the BVS group did not trans-
late into an increase in distal embolization with
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196no-reﬂow phenomenon. In particular, whereas pre-
procedure TIMI ﬂow was lower in the BVS than the
EES group, in contrast, post-procedure TIMI ﬂow was
not different between groups. This ﬁnding can be
explained either by higher use of GP IIb/IIIa inhibitors
or by the so-called snow racket effect of BVS on the
thrombus entrapped between the scaffold and the
vessel wall, due to the higher scaffold/vessel ratio of
BVS compared with EES (26% vs. 12%) (24).
STUDY LIMITATIONS. Due to the limited number
of patients and events, caution should be made
in reaching ﬁrm conclusions. Notably, this study
currently represents the largest cohort of STEMI
treated by BVS compared with a controlled arm.
Imbalance in the use of new antiplatelet agents, which
were not available at the time of the EXAMINATION
trial, should be taken into account in the results
interpretation, despite the adjusted Cox model.
Quantitative coronary angiography and device im-
plantation maximal pressures data were not collected,
as they were unavailable in the EXAMINATION trial. A
longer follow-up is needed to fully evaluate the per-
formance of this novel device in STEMI patients, as thephysiological advantages of BVS over metallic pros-
thesis seem to accrue at a follow-up longer than 1 year
(23,25,26).
CONCLUSIONS
The use of BVS in the setting of STEMI showed an
acceptable rate of DOCE at 30 days and 1 year,
compared with EES and BMS. However, rates of
BVS thrombosis, especially within 30 days after
implantation, were not negligible, compared with EES
and BMS.
Larger studies with longer follow-up are needed
to conﬁrm our preliminary ﬁndings and to fully
evaluate the performance of BVS in STEMI patients.
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